Therapeutic agents
AssigneeTrident Pharmaceuticals, Inc.
InventorsNEIL ANDREW WILLIAMS, TIMOTHY RAYMOND HIRST, TOUFIC OSMAN NASHAR
Life of this patent
Estimating the term…
Abstract
A method for treating an rheumatoid arthritis in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside GM-1 associated activity in an amount effective to treat the disease.
Claims17
A method for treating rheumatoid arthritis in a mammalian subject in need of the same wherein the method comprises:
- administering to the mammalian subject an agent capable of modulating a ganglioside GM-1 (GM-1) associated activity in an amount effective to treat the disease;
- wherein the agent, when in vivo, has an effect on GM-1 mediated intracellular signaling events;
- and wherein if the agent is for co-administration with an antigen, then the agent and the antigen are not so linked to form a single active agent.
Use of an agent in the preparation of a medicament to prevent and/or treat a rheumatoid arthritis condition;
- wherein the agent is capable of modulating a ganglioside GM-1 (GM-1) associated activity as determined by a reduction in the production of Th1 associated cytokines;
- wherein if the agent is for co-administration with an antigen, then the agent and the antigen are not so linked to form a single active agent;
- and wherein the modulation of the ganglioside associated activity affects the rheumatoid arthritis condition.
A method for treating rheumatoid arthritis in a mammalian subject in need of same wherein the method comprises:
- co-administering EtxB having ganglioside GM-1 (GM-1) binding activity, in an amount effective to treat the disease, and an antigen selected from the group of GAD, GAD65, IAA and insulin, to the mammalian subject in an amount effective to treat the disease;
- said antigen and said EtxB being not so linked to form a single active agent.
Dependencies are inferred from the claim text.